Global Commission on Drug Policy
Professional services
UnclaimedAn international panel of political leaders, public figures and experts advocating evidence-based, humane and health-oriented drug policy reform.
Last updated August 24, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
The Global Commission on Drug Policy (GCDP) is an international policy-reform commission composed of former heads of government, senior public officials, business leaders, human-rights advocates and intellectuals. Its secretariat is based in Geneva and the organization is hosted by the Geneva Graduate Institute. Rather than operating as a commercial brand, the commission functions as a high-profile advocacy and policy platform: it publishes reports, position papers and recommendations intended to shift international debate away from prohibition, militarized enforcement and the criminalization of personal drug use. The commission emerged from the experience of the Latin American Commission on Drugs and Democracy and was created to bring the discussion of drug policy to the international level. Its central argument is that decades of prioritizing punishment and supply suppression have not eliminated drug markets and have often intensified violence, corruption, mass incarceration, discrimination and public-health harms. The GCDP therefore promotes policies grounded in evidence, human rights and public health, including decriminalization of personal use, alternatives to incarceration, harm reduction, treatment and prevention, and forms of legal regulation for currently illicit psychoactive substances. Its first major international intervention came in 2011, when it declared that the global war on drugs had failed and argued that drug use that does not harm others should not automatically be treated as a criminal offense. The report drew attention because its signatories included highly senior former political leaders and other prominent public figures. It helped broaden the policy vocabulary around drug control by presenting reform not only as a civil-liberties issue but also as a matter of public health, security, development and institutional effectiveness. The commission subsequently expanded its program. Its 2014 report, Taking Control: Pathways to Drug Policies That Work, moved beyond criticism of prohibition and called for carefully designed legal regulation of psychoactive substances. Its 2016 report focused on decriminalization and the benefits of people-centered policies. A 2017 report examined how social perceptions and stigma surrounding drugs and people who use them obstruct evidence-based reform. In 2018, the commission published a detailed case for responsible regulation, including a transition from illegal markets to legally controlled systems and the implications for organized crime, vulnerable workers and state capacity. It has also addressed the North American opioid crisis and the relationship between drug policy and the Sustainable Development Goals. The GCDP has worked alongside and influenced a wider network of reform organizations, researchers and public advocates. Its reports have been cited in discussions in national governments, legislatures, media outlets and international forums, including the United Nations General Assembly Special Session on the world drug problem in 2016. The commission criticized the UNGASS outcome for failing to move decisively beyond the prohibitionist status quo. Its public positioning remains reformist rather than commercially competitive: it seeks to change the assumptions underlying drug-control systems and to encourage governments to adopt policies that reduce harm, protect rights and weaken the criminal incentives created by illegal markets.
History
The Global Commission on Drug Policy was established as an international continuation of reform discussions associated with the Latin American Commission on Drugs and Democracy. Its purpose was to place drug policy within a broader international conversation involving political leadership, public health, human rights, security and development. The organization is hosted by the Geneva Graduate Institute, while its secretariat carries out day-to-day operations from Geneva. The commission's public profile was established in June 2011 with a report that directly challenged the prevailing language of the global war on drugs. It concluded that decades of increasingly harsh enforcement had not achieved the stated objective of eliminating drug markets or use. Instead, according to the commission's analysis, prohibition and enforcement had helped produce violence, corruption, overcrowded prisons and other unintended consequences. The report advocated decriminalizing personal drug use where no other person was harmed and urged governments to replace reflexive punishment with prevention, treatment and harm reduction. The 2011 intervention generated substantial discussion among reform advocates, journalists, researchers and former political leaders. Jimmy Carter publicly endorsed the broad direction of the recommendations in a New York Times commentary, while analysts associated with U.S. drug-control institutions rejected the commission's conclusions and defended a more conventional enforcement-oriented framework. The report was also discussed by the Drug Policy Alliance, the Beckley Foundation's reform initiative and other organizations working on alternatives to prohibition. In 2013 and 2014, the commission's network and agenda were extended into West Africa through the West Africa Commission on Drugs, an initiative associated with former United Nations secretary-general Kofi Annan. This regional work reflected the GCDP's interest in how illicit markets, weak institutions, public-health challenges and international enforcement policies interact in vulnerable settings. In September 2014, the commission published Taking Control: Pathways to Drug Policies That Work. The report maintained the call for decriminalization and alternatives to incarceration but developed a stronger argument for legal regulation. It presented regulation as a possible means for governments to control product availability and quality, reduce the influence of criminal organizations and manage risks more transparently than an unregulated illicit market. The commission responded critically to the 2016 United Nations General Assembly Special Session on the world drug problem. It expressed disappointment that the agreed outcome did not adequately incorporate evidence, human rights or the growing international support for reform. The same year, it issued Advancing Drug Policy Reform: A New Approach to Decriminalization, which emphasized the social benefits of removing criminal penalties for personal consumption and possession and advocated policies centered on people rather than punishment. Its 2017 work broadened the analysis beyond laws and institutions. The World Drug Perception Problem examined how stigma and assumptions about drugs and people who use them shape public debate and make legislative reform more difficult. A separate position paper addressed the opioid crisis in North America, stressing that overdose emergencies require public-health tools rather than reliance on criminal sanctions alone. Another position paper connected drug control with the Sustainable Development Agenda, arguing that militarization and prohibition can undermine goals related to health, equality, poverty reduction, human rights and sustainable institutions. In 2018, the GCDP released Regulation: The Responsible Control of Drugs in Mexico City. This report offered a more detailed framework for moving from illegal markets toward legally regulated systems. It considered institutional capacity, the resilience of organized crime, the position of impoverished people working in illicit markets and the risks associated with regulating potentially dangerous products. The report also called for reform of the international drug-control architecture, which the commission viewed as an obstacle to coherent, health-oriented and rights-respecting policy. The commission has been successively chaired by Fernando Henrique Cardoso, Ruth Dreifuss and Helen Clark. Its membership has included former presidents and prime ministers from several regions, senior international officials, human-rights experts, economists, entrepreneurs and public intellectuals. The organization remains an advocacy and research body rather than a regulator, treatment provider or commercial product company. Its continuing role is to make high-level, evidence-based arguments for replacing punitive drug policy with approaches intended to reduce harm and improve public outcomes.
- 2018
Responsible regulation framework
[1]Regulation: The Responsible Control of Drugs presented a roadmap for governments seeking to control markets currently operated by criminal organizations.
- 2017
Focus expands to stigma, opioids and sustainable development
[1]The commission published work on public perceptions, the North American opioid crisis and the relationship between drug control and the Sustainable Development Goals.
- 2016
Decriminalization report and UNGASS response
[1]The GCDP published a new decriminalization report and criticized the UNGASS outcome for preserving too much of the prohibitionist status quo.
- 2014
Taking Control: Pathways to Drug Policies That Work
[1]The commission called for decriminalization, alternatives to incarceration and legally regulated approaches to psychoactive substances.
- 2013
West Africa work expands the reform agenda
[1]A related West Africa initiative associated with Kofi Annan extended international drug-policy reform discussions into the region.
- 2011
First major report challenges the global war on drugs
[1]The commission argued that punitive enforcement had failed and recommended decriminalization of non-harmful personal drug use alongside health-oriented responses.
Products and positioning
A high-profile, evidence-led international advocacy commission promoting decriminalization, harm reduction, public-health approaches and responsible regulation as alternatives to punitive prohibition.
Policy research · 2011
Global drug-policy reports
The commission's principal output is a series of high-level reports assessing the effects of prohibition and proposing alternatives. These publications combine political experience, public-health reasoning, human-rights analysis and institutional recommendations. They are designed for policymakers, international organizations, researchers, civil-society groups and media audiences rather than for commercial sale.
Policy advocacy
Position papers
Position papers apply the commission's reform framework to specific issues, including opioids, sustainable development and the operation of illegal drug markets. They generally emphasize harm reduction, human rights, public health and the need to replace ideological or purely punitive responses with policies that can be evaluated against measurable outcomes.
Marketing campaigns
- 2016UNGASS reform advocacy
Global
The commission advocated for a stronger role for health, human rights and evidence in the United Nations discussion on the world drug problem.
Outcome. The commission publicly expressed disappointment with the adopted outcome document, arguing that it did not sufficiently depart from prohibition.
- 2013West Africa drug-policy reform initiative
West Africa
The commission's reform agenda was extended through a West African initiative associated with Kofi Annan, addressing the interaction between drug markets, public health, governance and organized crime.
- 2011Global drug-war critique and decriminalization advocacy
Global
The GCDP used its membership of former national leaders and prominent experts to challenge the assumption that intensified enforcement could eliminate drugs. It promoted decriminalization of personal use, harm reduction and public-health responses.
Outcome. The report became a prominent reference point in international drug-policy reform debates and prompted supportive and critical responses in the United States and elsewhere.
Brand decisions
2018
Develop a roadmap for responsible regulationStrategyBackground
Illegal markets allow criminal organizations to control supply while governments lack direct control over product standards, access and public-health safeguards.
Action taken
The commission proposed legally regulated systems designed to weaken criminal markets while acknowledging risks, institutional limits and the effects on vulnerable workers.
Aftermath
The report became a detailed expression of the commission's long-term preference for controlled regulation over blanket prohibition.
2016
Reaffirm decriminalization after UNGASSStrategyBackground
The commission considered the United Nations special-session outcome insufficiently responsive to evidence and international reform efforts.
Action taken
It issued a report emphasizing the benefits of people-centered decriminalization and criticized the continued dominance of prohibitionist thinking.
Aftermath
The commission maintained pressure for reform in the international policy debate despite the limited change reflected in the UN outcome.
2014
Move from decriminalization advocacy toward responsible regulationStrategyBackground
The commission concluded that removing criminal penalties alone would not address the risks and incentives created by illicit markets.
Action taken
Taking Control proposed considering legally regulated markets for psychoactive substances, combined with public-health safeguards and alternatives to incarceration.
Aftermath
The commission's agenda expanded from opposing punitive prohibition to outlining institutional and regulatory alternatives.
2011
Adopt an international reform platform centered on decriminalizationStrategyBackground
The commission assessed decades of enforcement-led drug policy as ineffective and harmful to individuals and societies.
Action taken
It publicly called for decriminalizing personal use where others are not harmed and for expanding treatment, prevention and harm-reduction responses.
Aftermath
The position attracted international attention and became a foundation for the commission's later work on regulation and public-health policy.
- U.S. federal drug-control authorities — Officials rejected the commission's recommendations and defended a balanced drug-control framework that retained substantial enforcement measures.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/global-commission-on-drug-policy · Editorial policy · How profiles are compiled